Want to join the conversation?
Drugmaker $AGN reported a wider 2Q16 loss as results were impacted by loss of exclusivity on Namenda IR. Net loss widened to $571.3MM or $1.44 per share from $312.7MM or $0.80 per share last year. Revenue grew to $3.68Bil from $3.63Bil, on strong performance in key brands and new product launches. Non-GAAP EPS slid to $3.35 from $3.67.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?